RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VALABREGA G
Collezione AOU Città della Salute di Torino

Items : 9

Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2024 Feb 5;34(2):244-250. doi: 10.1136/ijgc-2023-004880.

2024
AOU Città della Salute di Torino

Cosma S; Cassoni P; Bertero L; Castellano I; Pino I; Valabrega G; Turinetto M; Piovano E; Leuzzi B; Bertschy G; Sciarrone A; Stura I; Mariani L; Preti M; Mancarella M; Borella F; Franchi D; Benedetto C;

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study. in Cancers / Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Borsotti L; Paolini B; Puppo A; Marinaccio M; Cormio G; Carella C; Mandato VD; Parisi A; Sikokis A; Biglia N; Mammoliti S; Zanchi L; Artioli G; Maldi E; Andreetta C; Raspagliesi F; Picardo E; Pignata S; Ghisoni E; Tuninetti V; Scotto G; Turinetto M; Sangiolo D; Di Maio M; Valabrega G;

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tuninetti V; Picardo E; Vertechy L; Bergamini A; Palaia I; Artioli G; Parisi A; Scandurra G; Scollo P; Baldoni A; Malaguti P; Cassani C; Zamagni C; Pisano C; Ricotti A; Marchetti C; Turinetto M; Scotto G; Scambia G; Pignata S; Valabrega G;

Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report. in Gynecologic oncology reports / Gynecol Oncol Rep. 2023 Jun 16;48:101220. doi: 10.1016/j.gore.2023.101220. eCollection 2023 Aug.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Valabrega G; Pasini B; Piva R; Turinetto M; Scotto G; Petracchini M; Palermo F; Siatis D; Vaira M; Tuninetti V; Zumstein L;

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. in Journal of ovarian research / J Ovarian Res. 2020 May 4;13(1):53. doi: 10.1186/s13048-020-00655-2.

2020
ASL VCO
AOU Città della Salute di Torino

Genta S; Tuninetti V; Giannone G; Ghisoni E; Maggiorotto F; Katsaros D; Sapino A; Borella F; Aglietta M; Senetta R; Fonte M; Scotto G; Gambino A; Goia M; Mittica G; Eusebi C; Momi M; Cassoni P; Valabrega G;

PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. in Cells / Cells. 2020 Feb 14;9(2):442. doi: 10.3390/cells9020442.

2020
AOU Città della Salute di Torino

D'Ambrosio C; Erriquez J; Arigoni M; Capellero S; Mittica G; Ghisoni E; Borella F; Katsaros D; Privitera S; Ribotta M; Maldi E; Di Nardo G; Berrino E; Venesio T; Ponzone R; Vaira M; Hall D; Jimenez-Linan M; Paterson AL; Calogero RA; Brenton JD; Valabrega G; Di Renzo MF; Olivero M;

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. in Journal of ovarian research / J Ovarian Res. 2018 May 30;11(1):42. doi: 10.1186/s13048-018-0415-y.

2018
AOU Città della Salute di Torino

Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R;

Androgen receptor status predicts development of brain metastases in ovarian cancers. in Oncotarget / Oncotarget. 2017 Jun 20;8(25):41143-41153. doi: 10.18632/oncotarget.17068.

2017
ASL Alessandria
AOU Città della Salute di Torino

Buosi R; Morra I; Manini C; Boldorini R; Genta S; Ghisoni E; Maggiorotto F; Aglietta M; Scotto G; Senetta R; Mittica G; Sapino A; Cassoni P; Valabrega G;

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. in Molecular oncology / Mol Oncol. 2014 Feb;8(1):20-6. doi: 10.1016/j.molonc.2013.08.013. Epub 2013 Sep 13.

2014
AOU Città della Salute di Torino

Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M;